https://doi.org/10.4081/hmr.v3i3.584

Hydroxyurea: the comparator in studies with new anti-JAK2 inhibitors

Vol. 3 No. 3: 7th Meeting New Insights in Hematology Venice, Italy, 26-29 April 2009
Published: June 12, 2009
Abstract Views: 229
PDF: 520
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

G Finazzi
support@pagepress.org
T Barbui
The fundamental discovery of V617F and other mutations in the JAK2 gene of most patients with Philadelphia-negative chronic myelo-proliferative neoplasms (MPNs) has changed the diagnostic approach to these disorders and opened the way to a molecularlytargeted therapy.1-6 A new generation of drugs with more or less specific inhibitory activity against JAK2 has been developed and it is now in advanced stages of clinical evaluation.7 As a rule, the efficacy and safety of a new therapeutic agent in a given disease should be compared with the best available treatment in randomized phase III clinical trials. In the most frequent MPNs, that are essential thrombocythemia (ET) and polycythemia vera (PV), the standard myelosuppressive therapy for patients with a high risk of thrombosis is hydroxyurea (HU). This drug is also the first choice for patients with myelofibrosis (MF) and symptomatic splenomegaly or requiring cytoreduction. The purpose of this chapter is to review the expected benefits and risks of HU in patients with MPNs in order to establish the bottom line for comparative studies with new drugs.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Finazzi, G., & Barbui, T. (2009). Hydroxyurea: the comparator in studies with new anti-JAK2 inhibitors. Hematology Meeting Reports (formerly Haematologica Reports), 3(3). https://doi.org/10.4081/hmr.v3i3.584
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).